JGH Open · 2021 · 22 citations · 12 references
PharmacyOncologyPharmacotherapyImmuno-oncology PharmacotherapyImmunotherapyTumor ImmunologyCalcineurin Inhibitor TherapyCalcineurin InhibitorsCancer ImmunotherapyCheckpoint Inhibitor TherapyGastrointestinal InflammationImmune Checkpoint InhibitorsCytotoxic T-lymphocyte-associated Protein 4 PathwayImmune Checkpoint Inhibitor-related ColitisMelanoma ImmunotherapyTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
BACKGROUND AND AIM: Immune checkpoint inhibitor (ICI) colitis is an increasingly common problem encountered as the use of checkpoint inhibitors (CPIs) grows in the management of cancers. Corticosteroids and tumour necrosis factor (TNF)-alpha inhibitors are widely recommended in the management of ICI colitis; however, the experience is limited when patients are refractory. Different authors have reported success with vedolizumab, mycophenolate, and cyclosporine. This case series describes our experience with calcineurin inhibitors in the management of corticosteroid and anti-TNF-alpha refractory ICI colitis. METHODS: Data from electronic medical records were identified and reviewed retrospectively from a cohort of patients treated at a single oncology center. All patients who were identified between March 2018 and May 2020 with ICI colitis refractory to treatment with infliximab and corticosteroids were included. RESULTS: There were 11 patients who developed ICI colitis after receiving CPIs for advanced melanoma and required rescue therapy with either cyclosporine or tacrolimus after treatment failure of infliximab. Median age was 53 (±8.48) years, with nine patients (81%) receiving combination Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) / programmed cell death protein 1 (PD-1) immunotherapy. Median time after first CPI infusion to ICI colitis was 4.43 (±19.53) weeks. The median time from onset of symptoms to commencement of rescue therapy with calcineurin inhibitors was 70 days (±66.06). Eight of the 11 patients (72.7%) responded to calcineurin inhibition. In patients who responded, calcineurin inhibitors were continued for a median of 54 (±28.96) days. CONCLUSION: The calcineurin inhibitors cyclosporine and tacrolimus appear to be a safe and effective option for the management of patients with infliximab-refractory ICI colitis. The therapeutic benefit is observed rapidly, and adverse effects appear to be limited with close monitoring.
12
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang, Hamzah Abu‐Sbeih, Emily Mao et al. · Inflammatory Bowel Diseases · 2018 · 244 citations
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist, Erik Hertervig, Peter Gedeon et al. · Cancer Immunology Immunotherapy · 2017 · 236 citations · Full text
Life Sciences, Immunology, Oncology +17
Tempei Miyaji, Yukiko Iioka, Yujiro Kuroda et al. · Journal of Patient-Reported Outcomes · 2017 · 209 citations · Full text